Intercell says Merck begins S.aureus vaccine trial
VIENNA, Aug 28 (Reuters) - Austrian biotech firm Intercell (ICEL.VI: Quote, Profile, Research, Stock Buzz) said on Thursday its partner Merck & Co (MRK.N: Quote, Profile, Research, Stock Buzz) has started a Phase II clinical trial to evaluate a vaccine candidate against Staphylococcus aureus infections.
The vaccine candidate is based on a conserved protein antigen discovered by Intercell and licensed to Merck in 2004.
Staphylococcus aureus is the most frequent cause of hospital-acquired infections, Intercell said in a statement.
This is the second trial start following a separate Phase II trial launch in December 2007.
Merck is responsible for clinical development, manufacturing and marketing of the vaccine. Intercell is eligible to receive milestone payments and royalties on future net sales. (Reporting by Karin Strohecker; Editing by Greg Mahlich)
© Thomson Reuters 2008 All rights reserved
Ads by Career Builder
Revenue Cycle Management/ Healthcare
Details: ...Growing Healthcare Consultancy organization...seeks experienced Healthcare Revenue Cycle Management...initiatives to healthcare providers and payers...
Work from Home as a Healthcare Recruiter
Details: ...from Home as a Healthcare Recruiter Health...an international healthcare recruiting and...represents high-demand healthcare professionals and...
Regional Operations Director - Healthcare
Details: ...Operations Director - Healthcare This position will...skills/experience: Healthcare Multi-Site Management...benefits including the healthcare industry's most...
Lawson Analyst - Payroll for healthcare
Details: ...experience within a healthcare industry environment...Application Analyst, Healthcare Systems, Payroll...Analyst - Payroll for healthcare position, and have...
Space beer lands in Japan
